Akkaraju Srinivas's Form 4 filing
Kalaris Therapeutics, Inc. (KLRS) · filed Feb 17, 2026
- Accession no.
- 0001231919-26-000166
- Filed
- Feb 17, 2026, 8:15 PM ET
- Trade date
- Dec 18, 2025
- Filing delay
- 61 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $5.00M. It was filed 61 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Akkaraju SrinivasCIK 0001253170 | Director, 10% Owner |
| Samsara BioCapital, L.P.CIK 0001699737 | 10% Owner |
| Samsara BioCapital GP, LLCCIK 0001888829 | 10% Owner |
| Samsara Opportunity Fund, L.P.CIK 0002086193 | 10% Owner |
| Samsara Opportunity Fund GP, LLCCIK 0002086456 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2025 | Common Stock | PPurchaseAcquired | +479,847 | $10.42 | +$5,000,005.74 | 1,979,847 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.